On Monday 22 November, we are pleased to welcome Professor Eran Segal from the Weizmann Institute of Science in Israel. Eran will showcase how his work on deep human phenotyping has been translated into several spin-out companies holding significant importance in the field of personalized medicine.
Through computational biology approaches, Eran Segal and his research team have developed revolutionizing predictive models that could be highly impactful in preventing disease and tailoring personal treatment plans based on each patient’s unique health profile. This paves the way for changing a “one size fits all” model that has permeated the health sector for decades.
Program of the day
15.30 Doors open
16.00 Introduction to BII and the subject of the day: Dr. Jens Nielsen
16.10 Keynote speaker: Dr. Eran Segal ‘Personalized medicine based on deep human phenotyping’
16.40 Fireside chat with Dr. Jens Nielsen and questions
17.00 Informal networking and closing reception
Please note that the event has free admittance with 60 tickets available. Please sign up quickly to secure your seat.
About Eran Segal
Dr. Eran Segal is a Professor in Computational Biology at the renowned Weizmann Institute of Science in Israel. He obtained his Ph.D. from Stanford University and has been awarded the Overton Prize by the International Society for Computational Biology. Furthermore, he is the founder of several biotech companies and a highly esteemed scientist in the synthetic biology space for his work on developing several quantitative models for all levels of gene regulation.
Over the years, he has published more than 140 articles in scientific and medical journals, many of those in high-impact factor papers such as Nature Cell Biology. As the mastermind of the Human Phenotype Project, he has been a frontrunner in using computational biology methods and data analysis to get closer to an answer on which aspects are fundamental drivers for diseases, such as obesity and diabetes. His findings have confirmed the potential of personalized medicine and challenge the ‘one size fits all paradigm’.